

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6901786

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
YUANYUAN ZHANG	11/11/2020
HAIXIA ZOU	11/11/2020
XINYU ZHAO	11/11/2020
YAOGUANG JIN	11/11/2020
XU CHEN	11/11/2020
PENG ZHAI	11/11/2020
WEI GUO	11/11/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BEIJING QL BIOPHARMACEUTICAL CO., LTD.
<b>Street Address:</b>	#101, BUILDING 7, 20 LIFE SCIENCE PARK ROAD, CHANGPING DISTRICT
<b>City:</b>	BEIJING
<b>State/Country:</b>	CHINA
<b>Postal Code:</b>	102206
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17467288
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	888 886 8168
<b>Email:</b>	patent@junhe.com
<b>Correspondent Name:</b>	JUN HE LAW OFFICES P.C.
<b>Address Line 1:</b>	20380 TOWN CENTER LANE
<b>Address Line 2:</b>	SUITE 128
<b>Address Line 4:</b>	CUPERTINO, CALIFORNIA 95014
<b>ATTORNEY DOCKET NUMBER:</b>	074585-8001US01
<b>NAME OF SUBMITTER:</b>	JAMES J. ZHU
<b>SIGNATURE:</b>	/James J. Zhu, Reg. No. 52,396/

<b>DATE SIGNED:</b>	09/06/2021
<b>Total Attachments: 5</b> source=8_Assignment_and_Declaration_074585-8001_final_signed#page1.tif source=8_Assignment_and_Declaration_074585-8001_final_signed#page2.tif source=8_Assignment_and_Declaration_074585-8001_final_signed#page3.tif source=8_Assignment_and_Declaration_074585-8001_final_signed#page4.tif source=8_Assignment_and_Declaration_074585-8001_final_signed#page5.tif	

## ASSIGNMENT

THIS ASSIGNMENT is by and among Zhang Yuanyuan, Zou Haixia, Zhao Xinyu, Jin Yaoquang, Chen Xu, Zhai Peng and Guo Wei residing at #101, building 7, 20 Life Science Park Road, Changping District, Beijing 102206, China (together "Assignors" ) and BEIJING QI BIOPHARMACEUTICAL CO., LTD. located at #101, building 7, 20 Life Science Park Road, Changping District, Beijing 102206, China ("Assignee").

The Assignors are the inventor of one or more inventions (the "Invention") described in:

A PCT Patent Application entitled "FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF", which was filed on December 31, 2019 with the Application No. PCT/CN2019/130668; and

a PCT Patent Applications entitled "FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF", which was filed on July 18, 2020 with the Application No. PCT/CN2020/102884; and

a PCT Patent Applications entitled "FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF", which is to be filed on December 29, 2020 with the Application No. PCT/CN2020/140532 (collectively, the "Applications"). The Assignors hereby authorize the Assignee to fill in the bibliographic information of the Applications when available.

The Assignee desires to acquire the entire right, title and interest in and to the Invention and the Applications, and in and to any patents (collectively, "Patents") that may be granted for the Invention and Applications in any and all countries and regions in the world.

Assignors acknowledge and agree that the Invention is a service invention made during the term of Assignors' employment by Assignee. Therefore, Assignors acknowledge and agree that Assignee owns the entire right, title and interest in and to the Invention and any and all patent applications and patent rights deriving from or relating to the Invention by operation of law pursuant to the laws of the People's Republic of China and other applicable laws upon creation of the Invention.

To the extent that any express assignment from Assignors to Assignee is necessary under any applicable laws and for valuable consideration, the receipt and sufficiency of which Assignors acknowledge, Assignors hereby sell, assign, and transfer to Assignee, its successors, legal representatives and assign, the entire right, title and interest in and to: the Invention, the Applications, and any Patents; any divisions, continuations, continuations-in-part of the

Applications, and any foreign applications of the Applications and any divisions, continuations, continuations-in-part of the foreign applications, and any other applications claiming priority rights from the Applications; any reissues, reexaminations, or extensions of any and all Patents; the right to file patent applications directly in the name of Assignee (in countries where such filings are permissible); and the right to claim priority rights deriving from the Applications (collectively, the "Rights"), whether now existing or hereafter arising.

Assignors warrant that they have not done and will not do anything to encumber the Rights. Assignors acknowledge and agree to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as Assignee deems necessary or desirable to: perfect Assignee's enjoyment of the Rights; prepare and prosecute the Applications or any other applications for Patents; conduct proceedings regarding the Rights, including any litigation, invalidation or derivation proceedings; or perfect or defend title to the Rights. Assignors request the Commissioner of Patents or any other office of similar authority to issue any Patents that may be issued on the Invention to Assignee. Assignors acknowledge and agree that Assignee shall have the rights to further assign or otherwise transfer any and all Rights to any third party and Assignors waive any right of first refusal that he may have for acquiring such Rights in the event of such assign or transfer to a third party.

#### DECLARATION OF INVENTOR(S)

As a named inventor, I hereby declare that: (1) This declaration is directed to the above-identified application; (2) the above-identified application was made or authorized to be made by me; (3) I believe that I am an original inventor or an original joint inventor of a claimed invention in the application. I hereby acknowledge that any willful false statements made in this declaration are punishable under 18 U. S. C. 1001 by fine or imprisonment of not more than five (5) years, or both.

As a named inventor below, I have reviewed and understand the contents of the application, including the claims, and am aware of the duty to disclose to the USPTO all information known to me to be material to patentability as defined in 37C.F.R. §1.56.

[Signature Pages Follow].

ASSIGNOR 1: Zhang Yuanyuan

Zhang Yuanyuan  
Signature

11 Nov. 2020  
Date

ASSIGNOR 2: Zou Haixia

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

ASSIGNOR 3: Zhao Xinyu

Zhao Xinyu  
Signature

11 Nov. 2020  
Date

ASSIGNOR 4: Jin Yaoguang

Jin Yaoguang  
Signature

11 Nov. 2020  
Date

ASSIGNOR 5: Chen Xu

Chen Xu  
Signature

20201111  
Date

ASSIGNOR 1: Zhang Yuanyuan

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

ASSIGNOR 2: Zou Haixia

Zou Haixia

\_\_\_\_\_  
Signature

Nov 11, 2020

\_\_\_\_\_  
Date

ASSIGNOR 3: Zhao Xinyu

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

ASSIGNOR 4: Jin Yaoguang

\_\_\_\_\_  
Signature


\_\_\_\_\_  
Date

ASSIGNOR 5: Chen Xu

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Date

ASSIGNOR 6: Zhai Peng

  
Signature



2020.11.11  
Date

ASSIGNOR 7: Guo Wei

  
Signature

2020.11.11  
Date

ASSIGNEE: BEIJING QL BIOPHARMACEUTICAL CO., LTD.

By:   2020.11.11  
Signature (Seal) Date

Zhang Xujia  
Print Name

Founder/CEO  
Title